Matthew D. Hellmann, MD
Ongoing analyses suggest enhanced clinical benefit is derived from the combined use of entinostat and pembrolizumab (Keytruda) in a subgroup of patients with PD-1/PD-L1–refractory non–small cell lung cancer (NSCLC) who have high levels of peripheral blood monocytes.
“Exploratory biomarker analysis is particularly critical in this population to guide development. We identified the baseline classification of monocyte may be associated with clinical benefit, although work is ongoing and needed to determine this as a prognostic or predictive association,” Hellmann said. “Overall, encouraged by the clinical activity here, future development plans for this combination are ongoing and will prospectively incorporate biomarker selection in this patient population.”
Hellmann M, Jänne P, Opyrchal M, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. Presented at: the IASLC 19th World Conference on Lung Cancer; September 23-26; Toronto, Canada. Abstract OA05.01.
... to read the full story